vTv Therapeutics (VTVT) Secures Global Partnership for PDE4 Inhibitor HPP737

vTv Therapeutics Inc. (NASDAQ:VTVT) is one of the most promising micro-cap stocks according to analysts. On February 2, vTv Therapeutics expanded its partnership with Newsoara Biopharma Co. Ltd., transforming a regional agreement into a global collaboration for the development of HPP737. Under the amended terms, Newsoara gains exclusive worldwide rights to develop and commercialize this novel PDE4 inhibitor. In exchange, vTv Therapeutics will receive an immediate $20 million upfront payment, with the potential for an additional $115 million in future development and sales milestones, plus tiered royalties on net sales.

HPP737 is a selective oral therapy designed to treat inflammation-mediated diseases, such as psoriasis, by inhibiting interleukin-23 and tumor necrosis factor alpha. While traditional PDE4 inhibitors are often limited by gastrointestinal side effects like nausea and vomiting, early clinical data suggest that HPP737 is well-tolerated and may avoid these common complications. This differentiated profile positions the drug as a potential best-in-class therapy within a historically restricted therapeutic target.

The $20 million influx strengthens vTv’s balance sheet as the company focuses on its primary clinical asset, cadisegliatin. Currently in Phase 3 trials, cadisegliatin is a liver-selective glucokinase activator being investigated as a first-in-class oral adjunctive therapy for type 1 diabetes. By using Newsoara’s development capabilities for HPP737, vTv Therapeutics Inc. (NASDAQ:VTVT) can prioritize its late-stage diabetes pipeline while maintaining a diversified source of long-term value through global milestones and royalties.

vTv Therapeutics Inc. (NASDAQ:VTVT) is a late-stage biopharmaceutical company that develops oral small-molecule drug candidates intended to treat people living with diabetes and other chronic diseases.